M.D. Anderson Cancer Center: Fallopian Tube Neoplasms trials

The registry lists 28 Fallopian Tube Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 5 are open to participants now and 7 have results posted.

Early Phase 1 4Phase 1 12Phase 2 12Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort StudyRecruitingNCT05287451Not applicable
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialRecruitingNCT04575935Phase 3
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
• Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFRecruitingNCT03604315Phase 1
• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results posted
• Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02520154Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Letrozole in Patients With Ovarian TumorsTerminatedNCT00505661Phase 2Results posted
• Chemoimmunotherapy Study for Patients With Epithelial Ovarian CancerCompletedNCT00501644Phase 2Results posted
• Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00317772Phase 1/2Results posted
• Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their RelativesCompletedNCT04257045
• Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
• Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryActive, not recruitingNCT02884648Phase 2
• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Active, not recruitingNCT02726997Phase 1/2
• Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02659241Early Phase 1
• Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT00634894Phase 2
• Depression Treatment and Screening in Ovarian Cancer PatientsActive, not recruitingNCT00515372Phase 1
• Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube CancerStatus unknownNCT00499512
• PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerTerminatedNCT00085384Phase 1/2
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1